Bedrijfsoverzicht
Hyperion DeFi, Inc. is an ophthalmic technology enterprise focused on the development and commercialization of specialized solutions within the United States market. The company primarily offers Optejet, which functions as a topical ophthalmic medication dispensing platform designed to deliver therapeutic agents effectively to the eye. This business operates within the healthcare sector, specifically targeting the biotechnology industry, which implies a focus on innovation-driven solutions rather than traditional manufacturing. The firm maintains a relatively small organizational scale with a market capitalization of $41.35 million and an annual revenue of $813,455 over the trailing twelve months. Hyperion DeFi, Inc. employs a workforce of nine individuals to execute its strategic initiatives. The current market capitalization and revenue figures indicate that the company is a micro-cap entity with limited operational footprint, suggesting high sensitivity to market sentiment and a reliance on successful product commercialization to expand its financial position.
Financiële gezondheid
The company reported total revenue of $813,455 for the trailing twelve months, yet it posted a net income of -$46,999,216 and an EBITDA of -$17,447,514. The substantial disparity between the modest revenue of approximately $813,000 and the net loss exceeding $46 million reveals a highly leveraged cost structure where operating expenses and R&D investments significantly outweigh current sales generation. Furthermore, the free cash flow stands at -$9,045,627, indicating a cash-burning business model that relies entirely on external capital or cash reserves to fund operations and development activities. Profitability metrics show a gross margin of 62.7%, which suggests efficient cost of goods sold management relative to revenue, while the operating margin of -3609.2% and profit margin of 0.0% highlight severe operational inefficiencies or high fixed cost burdens relative to the current sales base. Liquidity analysis shows the company holds $6.44 million in cash against $8.51 million in debt, resulting in a debt-to-equity ratio of 20.74 that characterizes a highly leveraged balance sheet rather than a conservative one. Despite the debt load, the current ratio of 2.68 indicates that the company possesses sufficient short-term assets to cover its short-term liabilities, providing a buffer for operational continuity. Return on Equity is reported at -324.1% and Return on Assets at -41.9%, metrics that collectively reveal management is currently destroying shareholder value and utilizing assets inefficiently to generate positive returns.
Waarderingsbeoordeling
Valuation multiples for Hyperion DeFi, Inc. are difficult to interpret using traditional earnings-based metrics, as the P/E Ratio (TTM) and Forward P/E are both N/A due to the lack of positive earnings. The price-to-book ratio is recorded at 0.77, indicating that the market is currently valuing the company at a discount to its net asset value, which may reflect market concerns regarding its high debt levels and negative equity generation. Alternative valuation metrics such as the price-to-sales ratio of 50.83 and the EV/EBITDA of -2.49 provide a different perspective, suggesting the market prices the stock based on revenue potential rather than profitability, though the negative EV/EBITDA underscores the company's lack of earnings power. The stock has exhibited significant price volatility within a 52-week range defined by a high of $17.18 and a low of $0.96. Trading relative to this range, the current price sits below the 52-week high, reflecting the market's current caution regarding the company's financial trajectory. The beta value of 2.63 indicates that the stock price is highly volatile and expected to move with more than double the magnitude of the broader market index, amplifying both potential gains and losses during periods of market movement.
Growth & Income
Revenue growth for the trailing twelve months is reported at an impressive 1666.4% year-over-year, likely driven by a base effect from minimal prior year sales or the inclusion of new commercial agreements. However, earnings growth is listed as N/A because the company has not yet generated positive earnings, making a direct comparison of earnings versus revenue growth impossible in traditional terms. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means all available cash flow is reinvested into operations and development rather than distributed to shareholders. This reinvestment strategy is typical for early-stage biotechnology firms that prioritize product development over immediate shareholder returns. Consequently, the overall growth and income profile is characterized by rapid top-line expansion offset by significant cash burn and an absence of current income generation or dividend distributions.